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ABSTRACT: Preeclampsia is a pregnancy-specific multiorgan disorder in which impaired
placental functioning and excessive oxidative stress play an important role. We previously
showed distinct differences between cerebrospinal fluid proteins in patients with preeclampsia
and normotensive pregnant women. An additional group of nonpregnant women was included
to study the presence of pregnancy-related proteins in normotensive and preeclamptic
pregnancies and whether pregnancy-related proteins were associated with preeclampsia.
Cerebrospinal fluid samples were tryptically digested and subsequently measured with a nano-
LC-tribrid Orbitrap mass spectrometry system. Proteins were identified by shotgun proteomic
analysis based on a data-dependent acquisition method. Proteins identified in preeclampsia,
normotensive pregnant controls, and nonpregnant groups were compared to the Progenesis
method according to the criteria as previously described and with a secondary analysis using a
Scaffold method including Benjamini−Hochberg correction for multiple testing. For
preeclampsia, the Progenesis and the Scaffold method together identified 15 (eight proteins
for both analyses with one overlap) proteins that were significantly different compared to normotensive control pregnancies. Three
of these 15 proteins, which were elevated in cerebrospinal fluid of preeclamptic women, were described to be pregnancy proteins
with a calcium-binding function. Using two analysis methods (Progenesis and Scaffold), four out of 15 differential proteins were
associated with pregnancy, as described in the literature. Three out of the four pregnancy-related proteins were elevated in
preeclampsia. Furthermore, the contribution of elevated (n = 4/15) and downregulated (n = 2/15) calcium-binding proteins in
preeclampsia is remarkably high (40%) and needs to be elucidated further.
■ INTRODUCTION
Preeclampsia (PE) is a major cause of maternal and fetal
morbidity and mortality.1 Two to eight percent of all
pregnancies are complicated by PE worldwide. The maternal
brain may be affected in severe PE, which might lead to major
cerebrovascular complications such as eclampsia and stroke.2−4
The exact biological pathway of PE and its complications in
the maternal brain have not been elucidated yet. These
complications may result from a disturbed autoregulatory
response of the brain to increased blood pressure and
generalized endothelial cell dysfunction. Endothelial cells play
a crucial role in the homeostatic regulation and stability of the
brain microenvironment.5,6 The endothelial cells of the blood−
brain barrier (BBB) are coupled by tight and adhered junctions
adhered to a basement membrane reducing paracellular
diffusion, preventing some blood constituents from passing
into the brain’s extracellular space.7 The BBB is a selective
barrier that controls the transport of molecules between the
vascular system and brain.8 Inflammatory cells and selected
proteins can penetrate the brain when the BBB is dysregulated,
causing immunological reactions, including edema and cell
death.9,10 PE is suggested to increase the BBB permeability in
an animal model,11 although this is not seen in preeclamptic
women.12
Cerebrospinal fluid (CSF), including proteins, surrounds the
brain and is partly produced in the brain by the choroid plexus
and partly in ependyma. The protein concentration in CSF is
approximately 100−200 times lower than in serum, which
enables easier detection of lower abundant proteins, and it is
assumed to be an approach to identify brain-derived proteins
that relate to brain pathology during the patient’s life.13,14 CSF
is in contact with neuronal tissue and will reflect to a certain
extent, the surrounding neuronal tissue content.15,16 Therefore,
investigating CSF might be useful to gain more insight into
brain pathophysiology during pregnancies complicated by PE.
A proteomic study that describes an overview of pregnancy
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proteins in CSF has not been described yet in the literature.
Also, the exact functions of these large numbers of pregnancy
proteins on brain function are still unknown.17 We previously
showed distinct differences between CSF proteins in patients
with PE and normotensive pregnant women. From these
proteins, AMBP was the most significant one.18 In the present
study, we included a nonpregnant control group to compare
also proteins in CSF between normotensive pregnant women
and nonpregnant women by shotgun proteomics technology.
In this way, we were able to study the effects of pregnancy on
the composition of CSF proteins in normotensive and
preeclamptic pregnancies.
■ RESULTS
The general patient characteristics are shown in Table S1,
clinical characteristics. Maternal age was not significantly
different in preeclamptic compared to normotensive pregnant
and nonpregnant women. Nonpregnant women smoked more
frequently compared to pregnant participants. Gestational age
at sampling and birth weight was lower in the PE group
compared to the pregnant women. The total protein
abundances (UV traces) in CSF between the three groups
were not significantly different, although a higher trend was
observed in nonpregnant women. Comparisons between
preeclamptic, normotensive, and nonpregnant women groups
were analyzed with the Progenesis and Scaffold method and a
part of the results compared to the previous study,18 as
illustrated in Scheme 1.
Pregnancy-Related Proteins in CSF. For protein
identifications, a shotgun proteomic analysis was performed
for each CSF sample from the preeclamptic, normotensive
pregnant, and nonpregnant women. The number of total
identified CSF proteins was 798, 802, and 746, respectively,
per group.
Significantly different proteins related to pregnancy were
identified through both methods, Progenesis (n = 23) and
Scaffold (n = 135). Pregnancy proteins mentioned in the
Scopus database were found by comparing normotensive
pregnant women with nonpregnant women. Both up- and
downregulated CSF proteins were found, as shown in Tables 1
and 2 for both methods, respectively.
When comparing normotensive pregnant women with
nonpregnant women, a 7% higher number of proteins were
identified in pregnant women. We observed that most of the
significantly different proteins analyzed by the methods
Progenesis (n = 20) and Scaffold (n = 81) were upregulated
in normotensive pregnant women, and, through IPA, that most
of the proteins are enzymes and might have a function in
protein synthesis (metabolism of proteins).
CSF Proteins in Preeclamptic Women Compared to
Normotensive Pregnant Women. Using the Progenesis
method, a total of 155 peptides were identified that were
significantly different (p < 0.01) in CSF between preeclamptic
and normotensive women; with a permutation test (n = 1000),
a background of 67 ± 30 was observed. The significant
peptides correlated to eight proteins that passed the criteria.
These proteins were considered as differentially abundant
between preeclamptic patients and normotensive pregnant
women. Four of these CSF proteins showed a higher
abundance in PE (Table 3).
Scaffold analysis between the preeclamptic group and the
normotensive pregnant group showed eight proteins, which
were significantly different after applying Benjamini−Hochberg
analysis correcting for multiple testing (Table 4).
Matrix GLA protein (MGP) was identified by both the
Progenesis method and the Scaffold method. We did not find
significant differences in the number of total proteins identified
in CSF of preeclamptic women compared to normotensive
pregnant women, 798 and 802, respectively.
For the comparison of CSF proteins in women with PE and
normotensive pregnant women, as also previously described,18
510 peptides (p < 0.01) corresponding to 17 significant
proteins were identified using only the Progenesis method.
The permutation test gave a range of 67 ± 28 peptides. Three
of the 17 significant proteins were higher represented in
nonpregnant women.
All peptides of the protein AMBP, analyzed as the most
significant differentially abundant protein in the previous
paper,18 were more abundant in preeclamptic women than in
the normotensive pregnant women (p = 0.041). However, the
protein did not pass the criteria for significance analyzed by the
Progenesis method in the present study. Although there was no
overlap with the significant differentially abundant proteins in
CSF of preeclamptic patients listed in Table 2 of the previous
work,18 all proteins (except one) mentioned in Table 2 showed
the same trends (i.e., up- or downregulated) in this study using
the Progenesis method. Moreover, the protein Amyloid-like
protein 1 was not found in the present study, but the protein
isoform Amyloid-like protein 2 instead (Table S4, Supporting
Information).
By the Progenesis and Scaffold methods, MGP passed the
criteria for significance and was upregulated in PE. MGP was
also significantly higher in preeclamptic women compared to
normotensive pregnant controls (p < 0.00010, Benjamini−
Hochberg) when analyzed by the Scaffold method (Figure 1).
Scheme 1. Flowchart of the Current Study in Comparison to the Previous Study
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Table 2. CSF Protein Comparison of Normotensive Pregnant and Nonpregnant Women Analyzed with the Scaffold Methoda,b

















score reference of first publication
prolactin PRL 2.50 ×
10−3
up 2.79 3624 48741 0.07 269.45 10.1210/endo-17-6-689
pregnancy zone protein PZP <1.00 ×
10−4
up 1.74 197 197 1.00 197.00 10.1016/0002-9378(64)
90712-4
fibronectin FN1 2.20 ×
10−3
down 0.91 643 4640 0.14 89.11 Kuusela et al., 1978
pregnancy-specific β-1-glycoprotein 1 PSG1 <1.00 ×
10−4
up 43.41 34 62 0.55 18.65 10.1016/0006-291X(89)
91105-4
sex hormone-binding globulin SHBG <1.00 ×
10−4





up 4.44 67 357 0.19 12.57 10.1002/pd.762
pregnancy-specific β-1-glycoprotein 9 PSG9 <1.00 ×
10−4





up 11.88 11 16 0.69 7.56 Kuroki et al., 1991
ceruloplasmin CP 2.50 ×
10−3
up 1.16 221 7444 0.03 6.56 10.3181/00379727-98-24117
pregnancy-specific β-1-glycoprotein 4 PSG4 <1.00 ×
10−4






up 81.57 21 90 0.23 4.90 10.1373/49.9.1445
pregnancy-specific β-1-glycoprotein 3 PSG3 <1.00 ×
10−4






up 21.41 6 9 0.67 4.00 10.1016/0006-291X(90)
92103-7
serum albumin ALB <1.00 ×
10−4
down 0.81 540 86 597 0.01 3.37 10.1111/j.0954-6820.1921.
tb15205.x
vitamin D binding protein GC 9.00 ×
10−4
up 1.14 62 1731 0.04 2.22 10.1210/jcem-45-2-225
72 kDa type IV collagenase MMP2 <1.00 ×
10−4





up 1.80 32 1128 0.03 0.91 10.1007/BF02211374
pregnancy-specific β-1-glycoprotein 2 PSG2 <1.00 ×
10−4
up 20.53 6 40 0.15 0.90 10.1016/0006-291X(90)
91455-2
afamin AFM 6.00 ×
10−4
up 1.34 9 96 0.09 0.84 10.1002/pd.2040
glutathione peroxidase 3 GPX3 <1.00 ×
10−4
up 2.73 20 488 0.04 0.82 Sunde et al., 1998
β-2-microglobulin B2M 7.00 ×
10−4
up 1.23 55 3794 0.01 0.80 10.3109/00365518109090529
bone marrow proteoglycan PRG2 <1.00 ×
10−4
up 5.90 5 33 0.15 0.76 10.1095/
biolreprod.110.090209
somatostatin SST 2.00 ×
10−4
up 2.30 153 32 876 0.00 0.71 Kumasaka et al., 1978
collagen α-1(III) chain COL3A1 4.20 ×
10−3
down 0.47 24 890 0.03 0.65 10.1002/(SICI)1096-8628
(19990212)82:4<305::AID-
AJMG6>3.0.CO;2-C
histidine-rich glycoprotein HRG <1.00 ×
10−4





down 0.69 17 505 0.03 0.57 10.1210/endo-127-5-2270
glutathione S-transferase P GSTP1 2.10 ×
10−3
up 1.82 43 3348 0.01 0.55 10.3109/10641959909023074
apolipoprotein A-I APOA1 2.00 ×
10−4
up 1.34 30 1725 0.02 0.52 PubMed ID: 8364102
corticosteroid-binding globulin SERPINA6 5.00 ×
10−4





down 0.36 13 371 0.04 0.46 10.1095/biolreprod62.5.1415
collagen α-1(I) chain COL1A1 4.00 ×
10−4
down 0.71 34 2994 0.01 0.39 PubMed ID: 2886666
collagen α-2(I) chain COL1A2 <1.00 ×
10−4
down 0.71 21 1270 0.02 0.35 PubMed ID: 2886666
α-1-antitrypsin SERPINA1 <1.00 ×
10−4
up 1.49 11 349 0.03 0.35 10.1016/j.ajog.2008.07.006
endothelial protein C receptor PROCR 1.30 ×
10−3
up 3.20 5 82 0.06 0.30 10.1160/TH-09-04-0224
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Table 2. continued

















score reference of first publication
growth arrest-specific protein 6 GAS6 1.40 ×
10−3
up 2.55 15 750 0.02 0.30 10.1152/ajplung.1998.275.6.
L1184
transgelin TAGLN <1.00 ×
10−4
up 3.56 6 143 0.04 0.25 10.1530/REP-09-0208
apolipoprotein E APOE <1.00 ×
10−4
up 1.27 69 19 608 0.00 0.24 PubMed ID: 8725150
clusterin CLU <1.00 ×
10−4
down 0.80 22 2311 0.01 0.21 10.1210/endo.136.12.7588296
serotransferrin TF <1.00 ×
10−4
up 1.16 7 253 0.03 0.19 10.1042/bj2570231




up 3.66 3 55 0.05 0.16 10.3321/j.issn:0529-
567x.2008.09.004
adipocyte enhancer-binding protein 1 AEBP1 <1.00 ×
10−4
down 0.20 3 64 0.05 0.14 10.1371/journal.pone.0027795
lymphatic vessel endothelial
hyaluronic acid receptor 1
LYVE1 1.80 ×
10−3













down 0.86 4 123 0.03 0.13 10.1095/
biolreprod.112.099564
renin receptor ATP6AP2 <1.00 ×
10−4
down 0.36 3 73 0.04 0.12 10.1016/j.
placenta.2014.09.004
14-3-3 protein zeta/delta YWHAZ <1.00 ×
10−4
up 2.19 6 349 0.02 0.10 10.1016/j.
placenta.2004.09.009
fibulin-2 FBLN2 4.00 ×
10−3
down 0.58 2 39 0.05 0.10 10.1007/s00018-014-1577-4
pleiotrophin PTN <1.00 ×
10−4
down 0.17 8 627 0.01 0.10 10.1210/endo.142.2.8111










up 1.27 3 122 0.02 0.07 10.1530/rep.0.1260621
interleukin-6 receptor subunit β IL6ST 4.30 ×
10−3
up 1.75 3 154 0.02 0.06 10.1530/REP-08-0437
β-2-glycoprotein 1 APOH <1.00 ×
10−4






up 3.41 2 77 0.03 0.05 10.1289/ehp.1307892
cadherin-18 CDH18 1.10 ×
10−3
up 1.45 1 20 0.05 0.05 10.1016/j.tjog.2018.08.023
L-lactate dehydrogenase A chain LDHA 8.20 ×
10−3






down 0.70 4 364 0.01 0.04 10.1371/journal.pone.0045224
peptidyl-prolyl cis-trans isomerase A PPIA 2.00 ×
10−4
up 1.97 4 424 0.01 0.04 10.1186/1471-2199-10-100
heat shock cognate 71 kDa protein HSPA8 3.20 ×
10−3
up 1.85 3 246 0.01 0.04 10.1007/s11033-012-2104-z
profilin-1 PFN1 2.00 ×
10−4
up 3.03 3 258 0.01 0.03 10.1371/journal.pone.0031418
glutaminyl-peptide cyclotransferase QPCT 1.30 ×
10−3










down 0.26 1 36 0.03 0.03 10.1089/scd.2013.0334
complement factor D CFD <1.00 ×
10−4





up 1.24 1 45 0.02 0.02 10.1016/j.
theriogenology.2016.10.007
apolipoprotein A-II APOA2 1.80 ×
10−3
up 1.46 2 188 0.01 0.02 10.1262/jrd.18002
matrix gla protein MGP 3.60 ×
10−3
down 0.42 4 863 0.00 0.02 10.1111/j.1834-7819.1994.
tb01379.x
α-enolase ENO1 <1.00 ×
10−4
up 2.68 4 922 0.00 0.02 10.1076/apab.110.1.94.897




down 0.30 1 87 0.01 0.01 10.3389/fgene.2019.00540
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The principal component analysis (PCA) for the compar-
ison of the preeclamptic, normotensive pregnant, and non-
pregnant women is shown in Figure 2. As expected, the
nonpregnant women (indicated in green) could be separated
from the PE (indicated in red) and normotensive pregnant
women (indicated in blue) groups. The preeclamptic women
clustered with the normotensive pregnant women, indicating
that there is no large difference between these two groups that
can be visualized directly by this PCA approach.
■ DISCUSSION
The analysis of CSF proteins in normotensive pregnant women
compared to nonpregnant women has not been described
previously. In CSF of normotensive pregnant women,
significantly different peptides and proteins were found to be
associated with pregnancy compared to nonpregnant women
using two methods (Progenesis method (n = 12) and Scaffold
method (n = 73)). The overlap of both methods based on
peptide and protein levels was low. The Progenesis method is
very restrictive, which may lead to a high rate of false negatives.
Using the Scaffold method, which includes Benjamini−
Hochberg correction for multiple testing, shows that the rate
of false negatives is low. The proteins identified by both
methods complement each other because one approach is
more focused on peptides (Progenesis method), and the other
approach (Scaffold method) is more focused on proteins.
Table 2. continued

















score reference of first publication
spondin-1 SPON1 <1.00 ×
10−4
down 0.23 1 90 0.01 0.01 10.1071/RD18114









up 1.79 2 471 0.00 0.01 10.1016/j.amjcard.2011.09.024
thrombospondin-2 THBS2 2.80 ×
10−3
down 0.26 1 161 0.01 0.01 10.1262/jrd.2016-056
basal cell adhesion molecule BCAM 4.60 ×
10−3
up 2.14 1 176 0.01 0.01 10.3233/CH-2011-1525
aA reference to the literature was included to define the association of the particular protein in pregnancy. bA total number of 135 proteins was
found with a p-value of less than p = 0.0086 (Benjamini−Hochberg) when comparing the normotensive pregnant women with nonpregnant
women. Seventy-three (out of 135) proteins were described in the literature as being associated with pregnancy listed above. Each protein was
ranked to their weighted score in the Scopus citation database search (November 2019) related to pregnancy. In the last column, the first published
paper is listed. As an example, prolactin has the highest score for a protein described to associate with pregnancy. Proteins (n = 62) with zero
counts (no association with pregnancy) for the weighted score are shown in Table S3, Supporting Information. CO = normotensive pregnant
women; NP = nonpregnant women.
Table 3. Differently Abundant Proteins (n = 8) in CSF of Women with Preeclampsia and Normotensive Pregnant Women, as
Analyzed by the Progenesis Methoda,b
protein name gene name up/down in PE fold change (PE/CO)
augurin C2orf40 PE 1.11
coagulation factor Xe F10 PE 1.41
matrix Gla proteinc,d,e MGP PE 2.13
osteomodulin OMD PE 1.25
cadherin-4e CDH4 CO 0.72
podocalyxin-like protein 2 PODXL2 CO 0.79
receptor-type tyrosine-protein phosphatase F PTPRF CO 0.65
nectin-1 PVRL1 CO 0.77
aCO = normotensive pregnant women. bPE = preeclamptic women. cSignificantly different protein as analyzed by Benjamini−Hochberg (p <
0.00055) using the Scaffold method. dRelated to pregnancy (see Table 1). eCalcium-binding protein.
Table 4. Differently Abundant Proteins (n = 8) in CSF of Women with Preeclampsia and Normotensive Women as Analyzed
by the Scaffold Methoda,b
protein name gene name up/down in PE t-test fold change (PE/CO)
actin, α skeletal muscle ACTA1 PE 1.60 × 10−4 1.48
basement membrane-specific heparan sulfate proteoglycan core proteine HSPG2 PE <1.00 × 10−4 1.72
fibromodulin FMOD PE <1.00 × 10−4 1.57
fibronectinde FN1 PE 1.40 × 10−4 1.11
matrix Gla proteinc,d,e MGP PE <1.00 × 10−4 3.80
transgelind,e TAGLN PE <1.00 × 10−4 2.98
chromogranin-A CHGA CO <1.00 × 10−4 0.77
peptidyl-glycine α-amidating monooxygenased PAM CO 4.50 × 10−4 0.77
aCO = normotensive pregnant women. bPE = preeclamptic women. cSignificantly different protein as analyzed by the Progenesis method. dRelated
to pregnancy (see Table 2). eCalcium-binding protein.
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When comparing CSF proteins of normotensive pregnant
women with nonpregnant women, we observed a total of 85
proteins that can be listed together by these two analyses as
pregnancy-associated proteins in CSF (according to the
literature). A higher number of proteins (7%), mostly
consisting of pregnancy-related proteins, was identified in
CSF of normotensive pregnant women compared to non-
pregnant women. Four significant differentially abundant
pregnancy-related proteins were found when comparing
preeclamptic women with normotensive pregnant women.
Three of these were calcium-binding proteins.
In our previous study,18 we compared CSF of women with
PE to CSF of normotensive pregnant women. In the present
study, we added a group of nonpregnant women. This addition
gives the possibility to study CSF pregnancy-related proteins
and proteins specifically associated with PE and not necessarily
related to pregnancy. In analogy to our previous study,18
peptides that belong to protein AMBP were significantly more
abundant in preeclamptic women than in the normotensive
pregnant women. However, this protein did not pass the
criteria for significance in the present study. An exact similar
trend for most proteins (24 out of 25 total) was observed,
although most relevant proteins mentioned in our previous
study lost their significance. This loss of significance may be
due to the lower number of samples used per group in the
present study. For that reason, it might show the same trend
for upregulation and downregulation of these proteins.
Notably, after comparing the preeclamptic women with the
normotensive pregnant women, more proteins (mainly
extracellular) related to cellular movement processes were
found to be upregulated in preeclamptic women (using the
Ingenuity software tool). The significant differentially abun-
dant proteins CDH4, F10, FN1, HSPG2 (also known as
Perlecan), MGP, and TAGLN (6 out of the 15 proteins
identified in both analytical methods) found in this study are
known to be calcium-binding proteins (Tables 3 and 4).19−24
MGP, using the Progenesis method and the Scaffold method,
was elevated in PE (fold changes of 2.13 and 3.80,
respectively). Although it is classified as a possible
pregnancy-related protein, it had a low weighted score for
literature mentioning pregnancy (0.02, Table 2). MGP protein
is part of the family of vitamin-K2-dependent GLA-(γ-
carboxyglutamic acids) containing proteins, which have a
high-affinity binding to calcium ions. It is secreted among
smooth muscle cells and plays an active role in angiogenesis.
Using the two analytical methods Progenesis and Scaffold, 3
out of the 15 proteins (FMOD, MGP, and TAGLN) elevated
in CSF of PE patients were associated with well-known
pregnancy proteins. TAGLN is an actin-binding protein that
belongs to the calponin family. Both proteins (TAGLN and
MGP) are expressed in smooth muscle cells of developing
vasculature and most likely contribute to vasculogenic
dysfunction of PE.21,25,26 Similar to MGP and TAGLN, the
differentially upregulated HSPG2 protein is also associated
with vascularity. This extracellular matrix protein has an active
role in vascular homeostasis. The FMOD protein, which was
also found to be differentially upregulated in PE, may play a
role in collagen fibrillogenesis. Assembly of extracellular matrix
and regulation of TGF-β activity are known processes of this
glycoprotein.27
The pregnancy-related proteins FN1, MGP, and TAGLN
were significantly differentially abundant in PE, as observed in
both analyses. From these two analyses in which 15 differential
abundant PE proteins were found together, 6 (CDH4, F10,
FN1, HSPG2, MGP, TAGLN) have an affinity to bind
calcium, as described above. The chance that a protein is
related to calcium-binding proteins just by chance with both
methods (Progenesis and Scaffold) is low. In five sets of 15
randomly taken proteins (from the total number of proteins
identified (n = 817)), we determined that (12 ± 6)% were
associated with calcium-binding (www.uniprot.org, searched
for the term calcium-binding). Thus, we can conclude that the
6 calcium-binding proteins of the 15 proteins found is a
significant finding. Most of the pregnancy-related proteins (n =
66) analyzed with both Progenesis and Scaffold methods were
not significantly different between preeclamptic women and
Figure 1. Normalized total spectra of MGP in the PE (red), CO
(blue), and NP (green) group. The empty bars indicate that the MGP
is too low or absent to be identified. Top: the number of identified
MGP containing samples per group.
Figure 2. PCA analysis for all three groups (preeclampsia, normotensive pregnant, nonpregnant) analyzed. Variance in the first direction is 14.3%,
and that in the second dimension is 10.5%. Groups indicated with red = preeclamptic women, blue = normotensive pregnant women, green =
nonpregnant women.
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normotensive pregnant women. Apart from the calcium-
binding proteins CDH4, F10, FN1, HSPG2, MGP, and
TAGLN found to be elevated in PE, it is tempting to speculate
that more calcium-binding proteins might be related to PE. For
instance, Calcyclin (S100A6) and Galectin 13 (PP13) are both
calcium-binding proteins that have been mentioned before to
be involved in PE.28,29 Calcium and magnesium are
administered to PE women. The literature shows that the
administration of calcium might have some beneficial effect,
but is not a remedy.30−34
Although the total protein abundances (UV peak areas)
were not significantly different between groups, the increase of
CSF protein identifications in pregnancy indicates the
possibility that the BBB permits passage of pregnancy-related
proteins. In normal pregnancy in animal models, the
permeability of the blood−brain barrier is described to be
increased.35,36 This change in permeability might also occur in
humans. In an animal study investigating arterial reactivity, the
permeability of the blood−brain barrier in PE was increased
compared with normal pregnancy.11 The albumin ratio is a
standardized biomarker value to determine the effect of
potential BBB damage.37,38 In this study, we did not find any
evidence of potential BBB damage in normotensive pregnant
women or women with PE related to serum albumin levels. On
the contrary, albumin levels were even significantly higher in
CSF of nonpregnant women. The observation that albumin is
even higher in nonpregnant women might be a homeostatic
compensation mechanism for the influx of pregnancy-related
proteins in CSF of pregnant women. A similar trend was
observed for immunoglobulins (upregulated in nonpregnant
women; Table S3).
The differences in the abundance of pregnancy-related
proteins might be explained through changes in the brain that
might occur during pregnancy.17 Apart from the fact that
specific protein hormones change during pregnancy in CSF,
research on relatively large numbers of pregnancy-associated
proteins in CSF is just absent or partially available. It is of
interest to study the precise functioning of these relatively large
numbers of pregnancy proteins in the brain.
Second, it is of interest to further study mechanisms in
which calcium and magnesium are incorporated in proteins
associated with PE as a function of calcium and magnesium
administration.
Strengths and Limitations of This Study. The strengths
included the high-resolution mass spectrometry (MS)
possibility of studying proteins and modifications in CSF
proteins. Also, it is difficult to investigate molecular effects of
pregnancy in the brain. Investigation of CSF proteins might be
a new possibility to study the brain of pregnant women and
preeclamptic women. Magnetic resonance imaging (MRI) can
provide information about the brain of pregnant women.17 The
possibility of investigating changes in the brain of women as a
function of CSF proteins and by MRI may result in
complementary information about women who suffer from
PE and severe brain complications.
Mass spectrometry analyses can result in different outcomes
depending on the analysis type used. If an analysis is focused
on particular peptides or proteins, the overlap in the shotgun
proteomic analysis is not high. This can be seen as a weakness
and also as a strength because multiple analyses may
complement each other as described above. Another weakness
is the performed survey of interactions between calcium and
magnesium concentrations and proteins as a function of
magnesium administration. In the present study, cluster
analysis of the group of preeclamptic women in which 24
out of the 30 patients were administered magnesium during
sampling did not show any clustering compared to women
with no magnesium administered. However, the number of
samples is limited to conclude about any possible interactions
between calcium and magnesium on protein level compared to
the administration of magnesium.
■ CONCLUSIONS
We found differentially abundant proteins between preeclamp-
tic women and normotensive pregnant women through both
analysis methods used (15 proteins, of which 6 were calcium-
binding). By comparing normotensive pregnant women with
nonpregnant women, a total of 158 CSF proteins were found
to be associated with pregnancy, from which 85 were
mentioned as pregnancy-associated in the literature. To our
knowledge, we showed for the first time that a 7% higher
number of pregnancy-associated proteins were present in CSF
of pregnant women. This 7% of proteins did not contribute to
the top 10% of most abundant proteins found in CSF.
■ MATERIAL AND METHODS
Samples. A part of randomly selected CSF samples was
used from the previous study to keep similar group size.18
Thirty out of 52 preeclamptic women, 30 out of 58
normotensive pregnant women, and an additional group of
29 nonpregnant women were obtained at two hospitals, the
Erasmus MC (Rotterdam, The Netherlands) and Maasstad
Hospital (Rotterdam, The Netherlands). After written consent,
a CSF sample (1 mL) was obtained during the spinal
anesthesia procedure before cesarean section in pregnant
women. In nonpregnant women, this sample was obtained
while performing spinal anesthesia for an elective surgical
procedure. The needle used during the spinal puncture was a
25 or 27 Gauge atraumatic needle. The CSF sample was
collected before the administration of anesthetics. Within 1 h
after sampling, the CSF samples were centrifuged, and cells in
the pellet were discarded. The CSF was aliquoted and stored
immediately at −20 °C and subsequently stored within 8 h at
−80 °C.
Approval for the study was given by the Ethics Board (MEC
2007-086 and MEC 2015-457).
Shotgun Proteomics. The samples were processed using
CSF digestion conform to the mass spectrometry (MS)
measurement protocol as previously described by van den Berg
et al.,18 with adjustments in Orbitrap instrument, LC-gradient,
and higher sample volume (3 μL). The shotgun proteomic
data have been deposited to the ProteomeXchange Con-
sortium via the PRIDE39 partner repository with the dataset
identifier PXD017862 and 10.6019/PXD017862.
The samples were enzymatically digested with trypsin and
subsequently measured with a nano-LC-Orbitrap MS/MS
mass spectrometry system (Ultimate 3000 HPLC, Thermo
Fisher Scientific, Germering, Germany; Orbitrap Lumos,
Thermo Fisher Scientific, San Jose, CA). Three-microliter
digest was loaded on a C18 trap column (C18 PepMap, 300
μm inner diameter (ID) × 5 mm, 5 μm particle size, 100 Å
pore size; Thermo Fisher Scientific, The Netherlands) and
desalted for 10 min using a flow rate of 20 μL/min 0.1% TFA.
The trap column was switched online with the analytical
column (PepMap C18, 75 μm ID × 250 mm, 2 μm particle,
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and 100 Å pore size; Dionex, The Netherlands) and peptides
were eluted with the following binary (A and B) gradient: 4−
38% solvent B in 90 min, whereby solvent A consists of 2%
acetonitrile and 0.1% formic in water and solvent B consists of
80% acetonitrile and 0.08% formic acid in water. The column
flow rate was set to 300 nL/min.
A data-dependent acquisition method was used for MS
detection: a high-resolution survey scan from 375 to 1500 Th.
was performed in the Orbitrap (value of target of automatic
gain control (AGC) 400 000) and a resolution 120 000 at 400
m/z; lock mass was set to 445.12003 u (protonated
(Si(CH3)2O)6). Based on this survey scan, the most intense
ions were consecutively isolated (AGC target set to 104 ions)
and fragmented by collision-activated dissociation (CAD)
applying 35% normalized collision energy in the linear ion trap
until a duty cycle time of 3 s was reached (top speed mode).
After precursors were selected for MS/MS, they were excluded
for further MS/MS spectra for 60 s.
Data Analysis. Data were analyzed in two ways: (1) for
peptide and subsequent protein identifications, the raw data
were processed and analyzed, as previously described18 using
Progenesis software (version 4.0, Nonlinear Dynamics, New-
castle-upon-Tyne, U.K.) (“Progenesis method”) and (2) using
Scaffold software (Proteome Software, version 4.7.2, Proteome
Software, Inc., Portland, OR) in which just proteins identified
by Mascot were loaded and analyzed (“Scaffold method”).
The identification of proteins through the Progenesis
method is a criteria-based analysis on peptide level.18 The
criteria were defined as: (1) 50% or more of the peptides of the
protein must have a low p-value (p < 0.05); (2) 30% of the
peptides of the protein must have a very low p-value (p <
0.01); and (3) 75% or more of the peptides of the protein
must be altered in the same direction between the groups. The
statistical background level was determined by performing a
permutation test using all samples randomly with an identical
analysis. The permutation test was repeated 1000 times, saving
the resulting thresholds with SD18 for determining the
significance value received from the actual experiment.
The identification of proteins through the Scaffold method is
directly based on protein level. The Scaffold method was
performed based on quantitative normalized spectral counts to
determine the abundances of identified proteins. The
significance of protein abundances between groups was
determined by a t-test corrected for multiple testing by
Benjamini−Hochberg analysis. This significance was calculated
in the Scaffold software program. A value below the false
discovery rate, as calculated by Benjamini−Hochberg analysis,
was considered to be significantly different. The abundance of
each protein is determined by calculating the fold change. Zero
counts were converted to 0.125 to enable log calculations.
In the present study, first, we searched for pregnancy-related
proteins by comparing the normotensive control pregnant
group (healthy pregnant) with nonpregnant women, using the
Progenesis and Scaffold methods. Proteins were considered to
be pregnancy-related if they were significantly up- or
downregulated in the normotensive pregnant group compared
to the nonpregnant group. Subsequently, each protein was
searched in the Scopus citation database to survey the relation
with pregnancy, and each protein was sorted according to their
weighted score. The number of pregnancy hits was counted by
searching the particular protein name combined with the word
“pregnancy” that was found either in the abstract or in the title
section of the selected publications (pregnancy in the protein
name itself was excluded in this literature search). The score
was calculated by the following formula: total number of
pregnancy hits * [total number of pregnancy hits/total number
of hits] for each protein separately. We used this formula to
prevent that a protein has a high percentage score if the total
number of hits and number of pregnancy hits were both
relatively low. Second, we compared the preeclamptic women
with the normotensive pregnant women by both Progenesis
and Scaffold methods.
Principal component analysis was performed for comparison
within the three groups, preeclamptic, normotensive pregnant,
and nonpregnant women. The Ingenuity Pathway Analysis
(IPA; www.qiagen.com) tool was used to get insight into the
functionality of proteins in CSF in women during pregnancy
and in women with PE. A flowchart of the various methods is
shown in Figure 3.
UV traces (peak areas (mAU*min)) from liquid chromatog-
raphy−mass spectrometry (LC−MS) measurements related to
preeclamptic, normotensive pregnant, and nonpregnant
women were compared to each other to determine the total
protein content in a fixed volume of 3 μL CSF. An analysis of
variance (ANOVA) t-test was performed to determine whether




The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acsomega.0c03910.
Clinical characteristics (Table S1); differently abundant
proteins in CSF of normotensive pregnant women and
nonpregnant women as analyzed by the Progenesis
Figure 3. Flowchart of data analysis. Progenesis and Scaffold methods
for the group comparisons of women with PE (preeclampsia, n = 30),
CO (normotensive pregnant women, n = 30), and NP (nonpregnant
women, n = 29). The extra group (NP) containing 29 subjects was
added to a part of the samples used in the previous study,18 which
included 52 (current n = 30) preeclamptic women and 58 (current n
= 30) normotensive pregnant women. The number of subjects in PE
and CO was reduced to keep comparable numbers in each group.
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method (Table S2); differently abundant proteins in
CSF of normotensive pregnant women and nonpregnant
women as analyzed by the Scaffold method (Table S3);
and comparison of proteins found in our previous study
with the current study (Table S4) (PDF)
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